Search
Learn how immunotherapy holds promise for transforming the treatment of gynecologic cancers.
A family of drugs developed at MSK targets disrupted processes in cells in diseases related to aging.
Advances in diagnostic and imaging modalities are making it possible to detect complex melanoma earlier, with greater accuracy, and are helping guide surgical approaches and patient monitoring plans.
Three emerging investigators are tackling the mysteries of biology and cancer at Memorial Sloan Kettering.
There is a clear and unmet need for less invasive and more accurate methods for diagnosing lung cancer. A promising innovation under investigation at Memorial Sloan Kettering Cancer Center (MSK) is the electronic nose (e-nose), which evaluates volatile organic compounds (VOCs) in exhaled breath. The e-nose platform detects a lung cancer-associated “breathprint” in breath from individuals with lung cancer.
MSK researchers shed light on how the number of mutations in a tumor affect a patient’s response to immunotherapy drugs.
Find out why you still need your routine mammogram, even during COVID-19.
Learn about Madeleine Ruff’s inspiring story, from being treated at MSK Kids for a rare cancer as a teenager to managing clinical trials for new cancer treatments as an adult.
Based a clinical trial conducted at MSK, the FDA has approved the targeted drug cobimetinib (Cotellic®) for treating a rare group of diseases known as histiocytoses, or histiocytic neoplasms in adults.
In order for immune cells to effectively kill cancer cells, a triad of three cells are necessary — a dendritic cell, a cytotoxic “killer” T cell, and a helper T cell, researchers at MSK and Baylor College of Medicine have found. The discovery could alter the way doctors administer immunotherapies.